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PHARMACOKINETICS OF CEFUROXIME ARE NOT SIGNIFICANTLY ALTERED BY 
CARDIOPULMONARY BYPASS IN CHILDREN
BACKGROUND
STUDY DESIGN
•Sternal
 
wound infections occur in 5% of all children after 
median sternotomy.1
 
Associated mortality is as high as 
60% in adults.2
•Surgical Infection Prevention (SIP) Project recommends 
cefuroxime
 
as a preferred antibiotic during cardiac surgery.3
•There are no published recommendations for the redosing
 of cefuroxime
 
during pediatric cardiac surgeries requiring 
CPB. Cephalosporins
 
display time-dependent PD, thus 
maintaining adequate concentrations throughout the entire 
surgery is essential.3
•
 
CPB related hemodilution
 
alters the volume of distribution 
of drugs, including cephalosporins
 
in one study. CPB may 
also sequester drug.4,5
•
 
Hypothermia during CPB may affect drug clearance via 
several mechanisms: decreasing hepatic and renal 
clearance and altered hepatic and renal blood flow.6
•
 
There are limited data describing CPB effects on pediatric 
prophylactic antibiotic therapy, and none of which describe 
cefuroxime.7
Patients
•Patients (n=15) scheduled to undergo a surgical 
procedure requiring cardiopulmonary bypass at Riley 
Hospital for Children, Indianapolis, IN 
•Study was approved by the Investigational Review Board 
at Indiana University-Purdue University-Indianapolis
•All parents/guardians provided written informed consent
•Exclusion Criteria:
• Allergy to beta-lactam
 
antibiotics
•Age less than 36 weeks gestational age or greater than 
3 years
•Anticipated CPB time less than 30 minutes
•History of culture positive for Methicillin-resistant 
Staphylococcus aureus
•Ventricular assist device therapy
•Cardiac transplantation
Experimental Protocol
•Patients received two doses of cefuroxime
 
as an IV 
bolus. The first dose of cefuroxime
 
(target: 25 mg/Kg) 
was administered prior to surgical incision and a second 
dose (target: 12.5 mg/Kg) was administered in the CPB 
prime solution.
•Serial blood samples were obtained, before, during, and 
after CPB
•Blood samples were collected into heparinized
 
blood 
collection tubes and the plasma was collected and stored 
frozen at -70 deg C until analysis. Samples were shipped 
on dry ice to the analytical laboratory.
Determination of Plasma Cefuroxime Concentrations
•Cefuroxime
 
concentrations were determined at the 
University of Cincinnati using reverse-phase HPLC assay 
with UV detection. 
•The standard curves were linear, and the intra-run and 
inter-run coefficients of variation were ≤
 
10%.
Pharmacokinetic Analysis
•Candidate pharmacokinetic models were fit to the 
cefuroxime
 
concentration-time date with ADAPT II using 
MAP Bayesian estimation.
•Model discrimination was accomplished by visual 
inspection of the predicted versus measured data, the 
distribution of the residuals, and the AIC.
•Two compartment model was chosen as the model of 
best fit.
•PK parameters: Vc
 
and Vp
 
(apparent volume of 
distribution in the central compartment and peripheral 
compartments respectively), and Cld
 
and Cls
 
(distribution 
clearance and systemic clearance, respectively).
•Secondary parameters: apparent steady-state volume of 
distribution (Vss), elimination rate constant and 
elimination half-life (t1/2) were calculated by standard 
equations.
•Simulations of a single-dose (25 mg/Kg pre-CBG) 
approach and a two-dose (25 mg/Kg pre and 12.5 mg/Kg 
prime solution dose) were performed.
RESULTS
SUMMARY
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Based upon the results of this study, the 
pharmacokinetics of cefuroxime
 
are not altered by CPB.
•Currently recommended pediatric doses of cefuroxime
 
(25-
 50mg/Kg) can be used in infants and children undergoing 
CPB to maintain adequate concentrations for surgical site 
infection prophylaxis.
•No indication of alteration in cefuroxime
 
PK during CPB.
STUDY OBJECTIVE
To determine the pharmacokinetics of cefuroxime
 
in 
pediatric patients undergoing open heart surgery with CPB.
Table 1, Patient Characteristics, n=15
Age (months) 13.2  +
 
9.2
Male (%) 53% 
Weight (Kg) 9.4 +
 
2.8kg
Duration of CPB (minutes) 145 +
 
77.5
Table 2, Pharmacokinetic Parameters, n=15
Dose 1
(mg/Kg)
Dose 1 
Cmax
 (mg/L)
Dose 2
(mg/Kg)
Cls
 (L/hr/Kg)
Vss
(L/Kg)
Vc
(L/Kg)
t1/2 
(hrs)
Median 24.2 344 12.5 0.050 0.213 0.072 3.76
Range 20.9-
 26.7
150-
512
0-
29.1
0.041-
 0.058
0.081-
 0.423
0.046-
 0.162
1.03-
 6.81
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Figure.  Simulation of 
cefuroxime concentrations 
based on median PK 
parameters in Table 2.
Table 3.  Simulated Cefuroxime Concentrations 
(mg/L)
Cmax C6 hour C8 hour
Single Dose 340.3 23.2 16.0
Two Dose 340.3 38.5 26.5
